Track Accuray Incorporated — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

Accuray Incorporated ARAY · Stock Open Accuray Incorporated in new tab

0.2672 USD
EPS
-0.40
P/B
0.62
ROE
-80.08
Beta
1.39
Loading chart...
Key Metrics
Earnings dateNov. 4, 2026
EPS-0.40
Book Value0.35
Price to Book0.62
Debt/Equity440.96
% Insiders4.364%
Growth
Revenue Growth-0.21%
Estimates
Forward P/E-0.90
Forward EPS-0.24

DCF Valuation

Tweak assumptions to recompute fair value for Accuray Incorporated (ARAY)
Currency: USD
DCF Assumptions
Decimal (e.g., 0.10 = 10%). Range allows declines (−50%) to strong growth (+50%).
Decimal (e.g., 0.30 = 30%).
Decimal (e.g., 0.04 = 4%).
Decimal (e.g., 0.20 = 20%).
Percent number (e.g., 3 = 3%).
Percent number (e.g., 10 = 10%).
Percent number (e.g., 5 = 5%).
DCF Result

Fair Value (DCF)
—
Current Price
—
Upside
—
WACC
—
Terminal PV
—
Σ PV of FCFs
—
Note: historical bars show reported FCF (for context); forward bars show PV of projected FCF; if no per-year data, totals are shown.

Accuray Incorporated Logo Accuray Incorporated Analysis (ARAY)

United States Health Care Official Website Stock

Is Accuray Incorporated a good investment? Accuray Incorporated (ARAY) is currently trading at 0.2672 USD.

Earnings Schedule: Accuray Incorporated is expected to release its next earnings report on Nov. 4, 2026. The market consensus estimate for Forward EPS is -0.24.

Investor FAQ

Does Accuray Incorporated pay a dividend?

No, it does not currently pay a dividend.

What asset class is Accuray Incorporated?

Accuray Incorporated is classified as a Stock. You can compare it against 3 other assets in the "Related Symbols" list on this page.

When is the next earnings date?

The next earnings date is projected to be Nov. 4, 2026. The company currently has a trailing EPS of -0.40.

Company Profile

Accuray Incorporated engages in the design, development, and sale of radiosurgery and radiation therapy systems for the treatment of tumors throughout the body in the United States, Canada, Latin America, Australia, New Zealand, Europe, the Middle East, India, Africa, Japan, and China. The company offers the CyberKnife platform, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of primary and metastatic tumors outside the brain, including tumors on or near the spine and in the breast, kidney, liver, lung, pancreas, and prostate. It also provides the TomoTherapy platform, including the Radixact System, a tailored helical solution, which integrates radiation treatment planning, delivery, imaging, and data management; iDMS data management system, a fully integrated treatment planning and data management systems; and Accuray precision treatment planning system, a treatment planning and data management systems. In addition, the company offers post-contract customer support, installation, training, and other professional services. It primarily markets its products directly to customers, including hospitals and stand-alone treatment facilities through its sales organization, as well as to customers through sales agents and group purchasing organizations in the United States; and to customers directly and through distributors and sales agents internationally. Accuray Incorporated was incorporated in 1990 and is headquartered in Madison, Wisconsin.

Exchange Ticker
NMS (United States) ARAY
FRA (Germany) XEJ.F
LSE (United Kingdom) 0H8I.L
Trades
No dividend information available for this instrument.
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Fundamentals

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion